

- B!*  
*Conced*
- a) administering a therapeutically effective dosage level to said human of said TNF antagonist; and
- b) administering said dose either intralesionally or perilesionally.

**REMARKS**

This Amendment is being filed in order to place this application in better form for examination purposes.

Respectfully submitted,

EZRA SUTTON, P.A.



EZRA SUTTON  
Reg. No. 25,770

Plaza 9, 900 Route 9  
Woodbridge, New Jersey 07095  
(732) 634-3520 PH/3511 FAX

ES/jmt

**REVISED VERSION OF CLAIM 39**

39 (amended). A method for inhibiting the action of TNF for treating a pathologic condition in a human, the pathologic condition being a disease or disorder which is caused or exacerbated by the action of said TNF by administering a TNF antagonist, defined as any of the following types of molecules directed against said TNF: a monoclonal antibody; a monoclonal antibody fragment; [soluble receptors]; or a fusion protein; comprising the steps of:

- a) administering a therapeutically effective dosage level to said human of said TNF antagonist; and
- b) administering said dose either intralesionally or perilesionally.